Ralph Bloomfield

TL;DR: In patients with moderate-to-severe Crohn's disease, induction and maintenance therapy with certolizumab pegol was associated with a modest improvement in response rates, as compared with placebo, but with no significant improvement in remission rates.

TL;DR: Patients with moderate-to-severe Crohn's disease who had a response to induction therapy with 400 mg of certolizumab pegol were more likely to have a maintained response and a remission at 26 weeks with continued certolIZumab Pegol treatment than with a switch to placebo.

TL;DR: These data suggest that patients treated with certolizumab pegol 400 mg earlier rather than later, with a confirmed Crohn's disease diagnosis, may achieve better treatment outcomes.

TL;DR: There were significantly greater rates of clinical remission at week 6 for CZP in patients with increased concentrations of C-reactive protein at entry, and future clinical trials should emphasize the treatment of patients who have objective evidence of inflammation in addition to symptoms of active disease.

TL;DR: Aliment Pharmacol Ther 2011; 33: 185–193